Wave Life Sciences Ltd. - Ordinary Shares (WVE): Price and Financial Metrics
GET POWR RATINGS... FREE!
WVE POWR Grades
- Growth is the dimension where WVE ranks best; there it ranks ahead of 89.79% of US stocks.
- The strongest trend for WVE is in Stability, which has been heading down over the past 177 days.
- WVE's current lowest rank is in the Stability metric (where it is better than 16.8% of US stocks).
WVE Stock Summary
- With a price/sales ratio of 96.25, WAVE LIFE SCIENCES LTD has a higher such ratio than 97.47% of stocks in our set.
- Equity multiplier, or assets relative to shareholders' equity, comes in at -37.86 for WAVE LIFE SCIENCES LTD; that's greater than it is for just 0.55% of US stocks.
- Revenue growth over the past 12 months for WAVE LIFE SCIENCES LTD comes in at -91.09%, a number that bests merely 1.35% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to WAVE LIFE SCIENCES LTD are CRIS, CRBU, EDIT, SQZ, and GWH.
- WVE's SEC filings can be seen here. And to visit WAVE LIFE SCIENCES LTD's official web site, go to www.wavelifesciences.com.
WVE Valuation Summary
- WVE's price/sales ratio is 96.2; this is 1946.81% higher than that of the median Healthcare stock.
- Over the past 90 months, WVE's EV/EBIT ratio has gone up 18.4.
Below are key valuation metrics over time for WVE.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| WVE | 2023-03-24 | 96.2 | -7.8 | -2.2 | -1.9 |
| WVE | 2023-03-23 | 101.4 | -8.2 | -2.3 | -2.0 |
| WVE | 2023-03-22 | 79.1 | -73.1 | -2.2 | -1.8 |
| WVE | 2023-03-21 | 88.3 | -81.5 | -2.4 | -2.0 |
| WVE | 2023-03-20 | 87.0 | -80.4 | -2.4 | -2.0 |
| WVE | 2023-03-17 | 83.3 | -76.9 | -2.3 | -1.9 |
WVE Growth Metrics
- The year over year cash and equivalents growth rate now stands at -58.45%.
- Its 3 year revenue growth rate is now at 166.66%.
- Its 5 year net income to common stockholders growth rate is now at -187.28%.
The table below shows WVE's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 4.175 | -101.374 | -152.899 |
| 2022-06-30 | 40.313 | -103.912 | -120.125 |
| 2022-03-31 | 42.714 | -84.491 | -117.595 |
| 2021-12-31 | 40.964 | -88.993 | -122.245 |
| 2021-09-30 | 48.638 | -113.375 | -116.249 |
| 2021-06-30 | 15.665 | -105.363 | -143.119 |
WVE's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- WVE has a Quality Grade of C, ranking ahead of 33.55% of graded US stocks.
- WVE's asset turnover comes in at 0.06 -- ranking 311th of 680 Pharmaceutical Products stocks.
- IONS, CORT, and CPIX are the stocks whose asset turnover ratios are most correlated with WVE.
The table below shows WVE's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.060 | 1 | -4.284 |
| 2021-03-31 | 0.061 | 1 | -4.798 |
| 2020-12-31 | 0.078 | 1 | -7.715 |
| 2020-09-30 | 0.050 | 1 | -5.619 |
| 2020-06-30 | 0.047 | 1 | -5.196 |
| 2020-03-31 | 0.055 | 1 | -4.843 |
WVE Price Target
For more insight on analysts targets of WVE, see our WVE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $9.86 | Average Broker Recommendation | 1.64 (Moderate Buy) |
WVE Stock Price Chart Interactive Chart >
WVE Price/Volume Stats
| Current price | $4.37 | 52-week high | $7.12 |
| Prev. close | $4.13 | 52-week low | $1.16 |
| Day low | $4.12 | Volume | 91,973 |
| Day high | $4.42 | Avg. volume | 438,810 |
| 50-day MA | $4.36 | Dividend yield | N/A |
| 200-day MA | $4.07 | Market Cap | 428.72M |
Wave Life Sciences Ltd. - Ordinary Shares (WVE) Company Bio
WAVE Life Sciences Pte. Ltd., a preclinical biopharmaceutical company, designs, develops, and commercializes nucleic acid therapeutic candidates. The company was founded in 2012 and is based in Simgapore.
Latest WVE News From Around the Web
Below are the latest news stories about WAVE LIFE SCIENCES LTD that investors may wish to consider to help them evaluate WVE as an investment opportunity.
Can Wave Life Sciences (NASDAQ:WVE) Afford To Invest In Growth?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Wave Life Sciences to Present at the Guggenheim Genomic Medicines and Rare Disease DaysCAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Guggenheim Genomic Medicines and Rare Disease Days in New York City on Monday, April 3, 2023 at 2:10 p.m. ET. A live webcast o |
Wave Life Sciences Ltd. (NASDAQ:WVE) Q4 2022 Earnings Call TranscriptWave Life Sciences Ltd. (NASDAQ:WVE) Q4 2022 Earnings Call Transcript March 22, 2023 Operator: Good morning, and welcome to the Wave Life Sciences Fourth Quarter and Full Year 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. As a reminder, this call is being recorded and webcast. I’ll now […] |
Wave Life Sciences (WVE) Reports Q4 Loss, Misses Revenue EstimatesWave Life Sciences (WVE) delivered earnings and revenue surprises of -11.90% and 47.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? |
Wave Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateAchieved clinical validation of PRISM platform in 2022 – demonstrated ability to potently and durably engage RNA targets and translate preclinical data to the clinic Extended leadership in RNA editing and advanced WVE-006 for AATD – first-in-class RNA editing candidate transitioning to clinical development in 2023 Initiating Part B of WVE-N531 study in exon 53-amenable DMD to assess dystrophin after 24 and 48 weeks of biweekly dosing Strategic collaboration with GSK underway, expected to add mul |
WVE Price Returns
| 1-mo | 4.05% |
| 3-mo | -37.57% |
| 6-mo | 21.05% |
| 1-year | 118.50% |
| 3-year | -53.36% |
| 5-year | -89.10% |
| YTD | -37.57% |
| 2022 | 122.93% |
| 2021 | -60.10% |
| 2020 | -1.81% |
| 2019 | -80.93% |
| 2018 | 19.77% |
Continue Researching WVE
Want to see what other sources are saying about Wave Life Sciences Ltd's financials and stock price? Try the links below:Wave Life Sciences Ltd (WVE) Stock Price | Nasdaq
Wave Life Sciences Ltd (WVE) Stock Quote, History and News - Yahoo Finance
Wave Life Sciences Ltd (WVE) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...